Reference
1. Bjorklund CC, Kang J, Amatangelo M, et al. Iberdomide (CC-220) is a
potent cereblon E3 ligase modulator with antitumor and immunostimulatory
activities in lenalidomide- and pomalidomide-resistant multiple myeloma
cells with dysregulated CRBN. Leukemia. 2020;34(4):1197-1201.
2. Matyskiela ME, Zhang W, Man HW, et al. A Cereblon Modulator (CC-220)
with Improved Degradation of Ikaros and Aiolos. J Med Chem.2018;61(2):535-542.
3. Rivellese F, Manou-Stathopoulou S, Mauro D, et al. Effects of
targeting the transcription factors Ikaros and Aiolos on B cell
activation and differentiation in systemic lupus erythematosus.Lupus Sci Med. 2021;8(1).
4. Werth V, Merrill J, Furie R, et al. OP0132 EFFECT OF IBERDOMIDE ON
CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A
24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY. Annals of the
Rheumatic Diseases. 2021;80(Suppl 1):76-77.
5. Thakurta A, Pierceall WE, Amatangelo MD, Flynt E, Agarwal A.
Developing next generation immunomodulatory drugs and their combinations
in multiple myeloma. Oncotarget. 2021;12(15):1555-1563.
6. van de Donk NWCJ, Popat R, Larsen J, et al. First Results of
Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and
Daratumumab (DARA) or Bortezomib (BORT) in Patients with
Relapsed/Refractory Multiple Myeloma (RRMM). Blood.2020;136(Supplement 1):16-17.
7. Maples KT, Joseph NS, Harvey RD. Current developments in the
combination therapy of relapsed/refractory multiple myeloma.Expert Rev Anticancer Ther. 2020;20(12):1021-1035.
8. Ye Y, Gaudy A, Schafer P, et al. First-in-Human, Single- and
Multiple-Ascending-Dose Studies in Healthy Subjects to Assess
Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of
Iberdomide, a Novel Cereblon E3 Ligase Modulator. Clin Pharmacol
Drug Dev. 2021;10(5):471-485.
9. Gaudy A, Atsriku C, Ye Y, et al. Evaluation of iberdomide and
cytochrome p450 drug-drug interaction potential in vitro and in a phase
1 study in healthy subjects. Eur J Clin Pharmacol.2021;77(2):223-231.
10. Lonial S, Donk NWCJvd, Popat R, et al. First clinical (phase 1b/2a)
study of iberdomide (CC-220; IBER), a CELMoD, in combination with
dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple
myeloma (RRMM). Journal of Clinical Oncology.2019;37(15_suppl):8006-8006.
11. Ayral G, Si Abdallah JF, Magnard C, Chauvin J. A novel method based
on unbiased correlations tests for covariate selection in nonlinear
mixed effects models: The COSSAC approach. CPT Pharmacometrics
Syst Pharmacol. 2021;10(4):318-329.
12. Evans ND, Godfrey KR, Chapman MJ, Chappell MJ, Aarons L, Duffull SB.
An identifiability analysis of a parent-metabolite pharmacokinetic model
for ivabradine. J Pharmacokinet Pharmacodyn. 2001;28(1):93-105.
13. Bertrand J, Laffont CM, Mentré F, Chenel M, Comets E. Development of
a complex parent-metabolite joint population pharmacokinetic model.Aaps j. 2011;13(3):390-404.
14. Niu J, Scheuerell C, Mehrotra S, et al. Parent-Metabolite
Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a
PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or
PARP-Sensitive Tumor Types. J Clin Pharmacol. 2017;57(8):977-987.
15. Connarn JN, Hwang R, Gao Y, Palmisano M, Chen N. Population
Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With
Hematologic Malignancies. Clin Pharmacol Drug Dev.2018;7(5):465-473.
16. Cheng Y, Chen J, Pourdehnad M, Zhou S, Li Y. Population
Pharmacokinetics of CC-122. Clin Pharmacol. 2021;13:61-71.
17. Li Y, Xu Y, Liu L, Wang X, Palmisano M, Zhou S. Population
pharmacokinetics of pomalidomide. Journal of clinical
pharmacology. 2015;55(5):563-572.
18. Cheng Y, Wang X, Tong Z, et al. Assessment of Transporter-Mediated
Drug Interactions for Enasidenib Based on a Cocktail Study in Patients
With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic
Syndrome. J Clin Pharmacol. 2021.
19. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P,
Vilarem MJ. Dual effect of dexamethasone on CYP3A4 gene expression in
human hepatocytes. Sequential role of glucocorticoid receptor and
pregnane X receptor. Eur J Biochem. 2001;268(24):6346-6358.
20. Villikka K, Kivistö KT, Neuvonen PJ. The effect of dexamethasone on
the pharmacokinetics of triazolam. Pharmacol Toxicol.1998;83(3):135-138.